Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant Acinetobacter baumannii Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant Acinetobacter baumannii Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration
Authors
Keywords
-
Journal
Open Forum Infectious Diseases
Volume 9, Issue 10, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-09-22
DOI
10.1093/ofid/ofac484
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii
- (2021) Jacinda C. Abdul-Mutakabbir et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration
- (2021) Andrew J. Fratoni et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration
- (2021) Emir Kobic et al. Open Forum Infectious Diseases
- Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives
- (2021) Davide Fiore Bavaro et al. Antibiotics-Basel
- Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections
- (2021) Pranita D Tamma et al. CLINICAL INFECTIOUS DISEASES
- Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia
- (2021) G. Dimopoulos et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol
- (2021) Milo Gatti et al. Journal of Global Antimicrobial Resistance
- Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists
- (2021) Jacinda C. Abdul-Mutakabbir et al. Infectious Diseases and Therapy
- PK/PD study on tigecycline in severely infected patients with continuous renal replacement therapy
- (2020) Hong-huan Zhao et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models
- (2019) Rio Nakamura et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
- (2018) Yutaka Saisho et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience
- (2018) Matteo Bassetti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
- (2016) Ryan K. Shields et al. CLINICAL INFECTIOUS DISEASES
- Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges
- (2016) Darren Wong et al. CLINICAL MICROBIOLOGY REVIEWS
- Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
- (2016) Takayuki Katsube et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy
- (2016) Derek N. Bremmer et al. PHARMACOTHERAPY
- In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria
- (2015) Akinobu Ito et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The FDA Reboot of Antibiotic Development
- (2013) David M. Shlaes et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started